Man Group plc Raises Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Man Group plc boosted its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 24.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 315,817 shares of the biopharmaceutical company's stock after buying an additional 61,123 shares during the quarter. Man Group plc owned approximately 0.26% of Catalyst Pharmaceuticals worth $6,591,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Barclays PLC increased its position in shares of Catalyst Pharmaceuticals by 129.4% during the 3rd quarter. Barclays PLC now owns 248,458 shares of the biopharmaceutical company's stock valued at $4,939,000 after purchasing an additional 140,129 shares during the last quarter. Dakota Wealth Management purchased a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter valued at $236,000. SG Americas Securities LLC increased its position in shares of Catalyst Pharmaceuticals by 276.7% during the 4th quarter. SG Americas Securities LLC now owns 32,812 shares of the biopharmaceutical company's stock valued at $685,000 after purchasing an additional 24,102 shares during the last quarter. Linden Thomas Advisory Services LLC increased its position in shares of Catalyst Pharmaceuticals by 21.3% during the 4th quarter. Linden Thomas Advisory Services LLC now owns 32,639 shares of the biopharmaceutical company's stock valued at $681,000 after purchasing an additional 5,732 shares during the last quarter. Finally, Toth Financial Advisory Corp increased its position in shares of Catalyst Pharmaceuticals by 7.4% during the 4th quarter. Toth Financial Advisory Corp now owns 54,250 shares of the biopharmaceutical company's stock valued at $1,132,000 after purchasing an additional 3,750 shares during the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on CPRX. Robert W. Baird raised their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research report on Monday, March 3rd. HC Wainwright reaffirmed a "buy" rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Wall Street Zen raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Stephens reissued an "overweight" rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Finally, Baird R W raised Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $32.29.

Catalyst Pharmaceuticals Stock Down 0.9%

CPRX traded down $0.21 during trading hours on Thursday, hitting $24.11. The stock had a trading volume of 912,598 shares, compared to its average volume of 1,105,894. The company's fifty day simple moving average is $23.49 and its 200 day simple moving average is $22.54. Catalyst Pharmaceuticals, Inc. has a 1 year low of $14.75 and a 1 year high of $26.16. The stock has a market cap of $2.94 billion, a PE ratio of 20.43, a price-to-earnings-growth ratio of 3.31 and a beta of 0.70.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 200,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $23.68, for a total transaction of $4,736,000.00. Following the completion of the transaction, the insider now owns 68,873 shares of the company's stock, valued at $1,630,912.64. The trade was a 74.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the sale, the insider now owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. This trade represents a 25.04% decrease in their position. The disclosure for this sale can be found here. Insiders sold 351,879 shares of company stock valued at $8,214,815 in the last quarter. 10.40% of the stock is currently owned by corporate insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.